WebApr 11, 2024 · Gain Therapeutics to Participate at the Jefferies Healthcare Conference. BETHESDA, Md., June 02, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. … WebApr 12, 2024 · BETHESDA, Md., April 12, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of allosteric small molecule therapies, today announced the appointment of C. Evan Ballantyne as the Company’s Chief Financial …
2024-04-14 NDAQ:HZNP Press Release Horizon Therapeutics …
WebWith the potential to address very large markets, Gain is initially focused on enzymes found in rare genetic diseases that share a genetic profile with more prevalent indications in order to most efficiently demonstrate proof of concept for its computational approach to drug discovery. ... ©2024 Gain Therapeutics, Inc. ... WebMar 23, 2024 · Gain's pipeline spans neurodegenerative diseases, lysosomal storage disorders (LSDs), metabolic disorders, as well as other diseases that can be targeted … adding an image to protonmail signature
8-K: Gain Therapeutics, Inc. - MarketWatch
WebMar 22, 2024 · Gain Therapeutics is redefining drug discovery with its SEE-Tx™ target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is … WebOn April 20th, 2024, Gain Therapeutics announced a multi-target drug discovery and development deal with Zentalis Pharmaceuticals to identify and address novel oncology targets. Gain will be using its proprietary Site-Directed Enzyme Enhancement Therapy (SEE-Tx™) computational platform technology to identify new and previously difficult-to ... WebMar 21, 2024 · Gain Therapeutics, Inc. is transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating … jftd 母の日